Clovis Oncology Inc. (NASDAQ:CLVS) has a beta of 1.66. The stock’s Relative Strength Index (RSI) is 48.86, with weekly volatility at 9.10% and ATR at 0.42. The CLVS stock’s 52-week price range has touched low of $4.08 and a $11.10 high. Its shares traded higher over the last trading session, gaining 4.45% on 05/14/21. The shares fell to a low of $5.68 before closing at $5.87. Intraday shares traded counted 3.21 million, which was 72.16% higher than its 30-day average trading volume of 11.54M. CLVS’s previous close was $5.62 while the outstanding shares total 104.25M.
Investors have identified the Biotechnology company Clovis Oncology Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $587.70 million, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Clovis Oncology Inc. (CLVS) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For CLVS, the company has in raw cash 190.92 million on their books with 64.28 million currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on an incline. In terms of their assets, the company currently has 252.51 million total, with 173.24 million as their total liabilities.
Having a look at the company’s valuation, the company is expected to record -1.32 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on CLVS sounds very interesting.
Is the stock of CLVS attractive?
In related news, See Remarks, IVERS-READ GILLIAN C sold 3,952 shares of the company’s stock in a transaction that recorded on May 04. The sale was performed at an average price of 5.54, for a total value of 21,894. As the sale deal closes, the See Remarks, MUEHL DANIEL W now sold 4,837 shares of the company’s stock, valued at 26,797. Also, See Remarks, Rolfe Lindsey sold 4,501 shares of the company’s stock in a deal that was recorded on May 04. The shares were price at an average price of 5.54 per share, with a total market value of 24,936. Following this completion of acquisition, the See Remarks, Harding Thomas C. now holds 80 shares of the company’s stock, valued at 443. In the last 6 months, insiders have changed their ownership in shares of company stock by 0.40%.
1 out of 7 analysts covering the stock have rated it a Buy, while 3 have maintained a Hold recommendation on Clovis Oncology Inc.. 2 analysts has assigned a Sell rating on the CLVS stock. The 12-month mean consensus price target for the company’s shares has been set at $7.13.